Repository logo
Log in(current)
Repository logoMIT Open ScholarshipDSpace@MIT
  1. Home
  2. MIT Open Access Articles
  3. MIT Open Access Articles
  4. Molecular bottlebrush prodrugs as mono- and triplex combination therapies for multiple myeloma

Molecular bottlebrush prodrugs as mono- and triplex combination therapies for multiple myeloma

Thumbnail Image
Download
Name

nihms-1877310.pdf

Description
Accepted version
Size

1.78 MB

Format

Adobe PDF

Checksum (MD5)

f910dac930e01df3eda4e403e281cf31

Author(s)
Detappe, Alexandre
•
Nguyen, Hung V-T
•
Jiang, Yivan
•
Agius, Michael P
•
Wang, Wencong
•
Mathieu, Clelia
•
Su, Nang K
•
Kristufek, Samantha L
•
Lundberg, David J
•
Bhagchandani, Sachin
more
Date Issued
February 26, 2023
Journal
Nature Nanotechnology
Publisher
Springer Science and Business Media LLC
Citation
Detappe, A., Nguyen, H.VT., Jiang, Y. et al. Molecular bottlebrush prodrugs as mono- and triplex combination therapies for multiple myeloma. Nat. Nanotechnol. 18, 184–192 (2023).
Version
Author's final manuscript
Abstract
Cancer therapies often have narrow therapeutic indexes and involve potentially suboptimal combinations due to the dissimilar physical properties of drug molecules. Nanomedicine platforms could address these challenges, but it remains unclear whether synergistic free-drug ratios translate to nanocarriers and whether nanocarriers with multiple drugs outperform mixtures of single-drug nanocarriers at the same dose. Here we report a bottlebrush prodrug (BPD) platform designed to answer these questions in the context of multiple myeloma therapy. We show that proteasome inhibitor (bortezomib)-based BPD monotherapy slows tumour progression in vivo and that mixtures of bortezomib, pomalidomide and dexamethasone BPDs exhibit in vitro synergistic, additive or antagonistic patterns distinct from their corresponding free-drug counterparts. BPDs carrying a statistical mixture of three drugs in a synergistic ratio outperform the free-drug combination at the same ratio as well as a mixture of single-drug BPDs in the same ratio. Our results address unanswered questions in the field of nanomedicine, offering design principles for combination nanomedicines and strategies for improving current front-line monotherapies and combination therapies for multiple myeloma.
Terms of Use
Article is made available in accordance with the publisher's policy and may be subject to US copyright law. Please refer to the publisher's site for terms of use.
Persistent DSpace Link
https://dspace.mit.edu/handle/1721.1/170716
DOI of Published Version
https://doi.org/10.1038/s41565-022-01310-1
Repository logo
PrivacyPermissionsAccessibilityContact us
Repository logo
Notify us about copyright concerns.